QuidelOrtho Corporation (NASDAQ:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that its board of directors has authorized the repurchase of up to $300 million of shares of QuidelOrtho’s common stock over the next two years.
Airbus’ Strategic Pivot: Appoints Christian Scherer As CEO Of Commercial Aircraft Business
Airbus SE (OTC: EADSY) is undergoing a significant leadership reshuffle within its Executive Committee, primarily focusing on strengthening its Commercial Aircraft business
